| Seizures, Focal
Aptiom vs Qudexy XR
Side-by-side clinical, coverage, and cost comparison for seizures, focal.Deep comparison between: Aptiom vs Qudexy with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsQudexy has a higher rate of injection site reactions vs Aptiom based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Qudexy but not Aptiom, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Aptiom
Qudexy
At A Glance
Oral
Once daily
Sodium channel inhibitor
Oral
Once daily
Broad-spectrum anticonvulsant
Indications
- Seizures, Focal
- Seizures, Focal
- Generalized seizures
- Lennox-Gastaut syndrome
- Migraine Disorders
Dosing
Seizures, Focal (Adults) Initial 400 mg orally once daily; may initiate at 800 mg once daily if need for seizure reduction outweighs increased adverse reaction risk; increase weekly by 400-600 mg to recommended maintenance of 800-1600 mg once daily.
Seizures, Focal (Pediatric, 4-17 years) Weight-based once daily oral dosing; initial dose and titration increments per weight table; maintenance 400-1200 mg/day depending on body weight range (11-21 kg: 400-600 mg; 22-31 kg: 500-800 mg; 32-38 kg: 600-900 mg; >38 kg: 800-1200 mg).
Renal Impairment (Moderate or Severe) Reduce dosage by 50% in patients with creatinine clearance below 50 mL/min.
Seizures, Focal, Generalized seizures, Lennox-Gastaut syndrome Monotherapy (adults and peds >=10 years): 400 mg orally once daily, titrated over 6 weeks from 50 mg/day; peds 2-9 years: weight-based 150-400 mg/day once daily. Adjunctive (adults): 200 to 400 mg once daily; adjunctive (peds 2-16 years): approximately 5 to 9 mg/kg once daily, not to exceed 400 mg/day.
Migraine Disorders 100 mg orally once daily for patients 12 years of age and older, titrated over 4 weeks from 25 mg/day.
Contraindications
- Hypersensitivity to eslicarbazepine acetate or oxcarbazepine
- History of hypersensitivity reaction to topiramate, QUDEXY XR, or any inactive ingredient
Adverse Reactions
Most common (>=4%) dizziness, somnolence, nausea, headache, diplopia, vomiting, fatigue, vertigo, ataxia, blurred vision, tremor
Serious suicidal behavior and ideation, serious dermatologic reactions, DRESS/multiorgan hypersensitivity, anaphylactic reactions and angioedema, hyponatremia, drug-induced liver injury, abnormal thyroid function, pancytopenia, agranulocytosis, leukopenia
Postmarketing leukopenia, agranulocytosis, thrombocytopenia, megaloblastic anemia, pancytopenia, syndrome of inappropriate antidiuretic hormone secretion (SIADH)
Most common (>=10%) Paresthesia, somnolence, dizziness, weight loss, anorexia, speech disorders/related speech problems, psychomotor slowing, nervousness, vision abnormal
Serious Acute myopia and secondary angle closure glaucoma, visual field defects, oligohydrosis and hyperthermia, metabolic acidosis, suicidal behavior and ideation, cognitive/neuropsychiatric adverse reactions, decrease in bone mineral density, negative effects on growth, DRESS/multiorgan hypersensitivity, serious skin reactions, anaphylaxis and angioedema, hyperammonemia and encephalopathy, kidney stones, hypothermia with concomitant valproic acid
Postmarketing Hepatic failure, hepatitis, pancreatitis, bullous skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis), pemphigus, maculopathy, nephrocalcinosis
Pharmacology
APTIOM is extensively converted to its active metabolite eslicarbazepine after oral administration; eslicarbazepine exerts anticonvulsant activity thought to involve inhibition of voltage-gated sodium channels.
Topiramate blocks voltage-dependent sodium channels, augments GABA-A receptor activity, antagonizes the AMPA/kainate subtype of the glutamate receptor, and inhibits carbonic anhydrase isozymes II and IV; the precise mechanisms underlying its anticonvulsant and preventive migraine effects are unknown.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Aptiom
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (0/12) · Qty limit (0/12)
Qudexy
- Covered on 5 commercial plans
- PA (7/12) · Step Therapy (0/12) · Qty limit (0/12)
UnitedHealthcare
Aptiom
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (0/8) · Qty limit (3/8)
Qudexy
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Aptiom
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Qudexy
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$35/fillfill
Aptiom High-Deductible Discount CardCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
No savings programs available for Qudexy.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
AptiomView full Aptiom profile
QudexyView full Qudexy profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.